1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jilin Jian Yisheng Pharmaceutical Co., Ltd. Class A

Jilin Jian Yisheng Pharmaceutical Co., Ltd. Class A

SSZSE:002566
6.59
CNY
+0.09
(+1.38%)
0.12EPS
51.78P/E
2.00BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.92
2.37
2.48
2.84
3.13
2.95
3.06
2.55
2.65
2.51
2.58
2.02
1.93
2.03
Basic EPS, GAAP
0.26
0.29
0.03
0.04
0.18
0.21
0.23
0.24
0.29
0.25
0.29
0.16
0.09
0.12
Free Cash Flow per Basic Share
-0.78
-1.99
-1.29
-0.22
0.57
0.28
0.57
0.39
0.33
0.32
0.52
0.13
0.26
- -
Dividend per Share
- -
0.1
0.17
0.11
0.09
0.12
0.05
0.09
0.07
0.07
0.09
0.19
0.14
0.21
Book Value per Share
5
5.23
5.21
5.26
5.45
5.61
5.84
6.03
6.29
6.51
6.75
6.76
6.74
6.74
Tangible Book Value per Share
4.95
5.17
5.02
5.08
5.27
5.43
5.67
5.65
5.92
6.15
6.4
6.41
6.41
6.41
Basic Weighted Avg Shares
336
332
331
331
331
331
331
331
331
331
331
331
331
331
Sales/Revenue/Turnover
644
788
820
939
1,034
975
1,013
843
878
830
854
668
640
671
Operating Margin (%)
9.73
11.9
6.49
7.99
14.17
15.06
14.64
15.28
15.11
13.01
12.4
8.72
6.07
5.86
Depreciation Expense
19
23
24
31
40
40
42
41
43
44
49
47
43
- -
Net Income, GAAP
87
96
11
13
60
69
77
80
96
83
95
52
29
39
Effective Tax Rate (%)
14.58
12.67
31.49
45
15.25
15.2
14.6
14.68
15.14
12.75
14
14.93
3.76
5.67
Profit Margin (%)
13.56
12.24
1.33
1.41
5.81
7.08
7.56
9.5
10.94
10.01
11.1
7.79
4.53
5.75
Working Capital
1,358
1,392
1,297
1,319
1,399
1,472
1,587
1,646
1,688
1,714
1,841
2,010
2,014
2,026
LT Debt
2
2
2
1
1
10
13
10
11
10
4
156
135
134
Total Equity
1,677
1,751
1,745
1,801
1,897
1,966
2,058
2,132
2,198
2,249
2,332
2,333
2,329
2,331
Return on Invested Capital (%)
4.15
4.29
0.11
0.18
3.46
3.74
4
3.83
4.24
3.39
3.64
1.88
1.1
1.45
Return on Capital (%)
5.19
5.35
1.62
1.16
2.47
2.99
3.17
3.33
3.82
3.4
3.82
2.34
1.49
1.71
Return on Common Equity (%)
5.42
5.69
0.63
0.76
3.39
3.78
4.04
4.08
4.71
3.92
4.32
2.33
1.3
1.72

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
291
336
332
LT Borrowings
130
130
130
LT Finance Leases
5
3
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
331
331
331
Market Capitalization
2,525
2,684
1,999

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,398
2,454
2,449
Cash, Cash Equivalents & STI
571
635
625
Accounts Receivable, Net
158
173
184
Inventories
1,581
1,575
1,572
Total Current Liabilities
384
419
422
Payables & Accruals
- -
- -
- -
ST Debt
291
336
332
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.94%
1.8%
-0.18%
Free Cash Flow
-35.38%
14%
97.89%
Net Income, GAAP
33.77%
-13.77%
-44.32%
Sales/Revenue/Turnover
-1.83%
-4.87%
-4.23%
Total Cash Common Dividend
8.43%
17.39%
-26%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
200
147
158
163
668
2025
159
169
- -
164
640
2026
179
160
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.04
0.01
0.05
0.16
2025
0.04
0.02
- -
0.01
0.09
2026
0.05
0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.16
0.01
- -
0.19
2025
0.01
0.11
- -
0.01
0.14
2026
0.01
0.09
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xiao Min Xie
Full Time Employees
1,616
Sector
Health technology
Industry
Pharmaceuticals: major
Address
17-20 Wenhua East Road Ji'an JI China 134200
IPO Date
Mar 8, 2011
Website
yisheng-pharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ) develops, manufactures, and markets pharmaceutical products primarily focused on anti-tumor, cardiovascular, and anti-infective therapies. The company offers a diverse portfolio including small-molecule chemical drugs such as tyrosine kinase inhibitors for cancer treatment, like icotinib hydrochloride under the Conmana brand; cardiovascular agents including compound danshen dripping pills and salvianolate injections; anti-infective medications such as cefmenoxime hydrochloride injections; and traditional Chinese medicine formulations targeting respiratory and digestive disorders. It also provides contract development and manufacturing organization (CDMO) services for APIs and intermediates, alongside medical devices and health products. Founded in 2002 and headquartered in Jilin City, Jilin province, China, the company operates principally in the domestic Chinese market with expanding international presence through exports to Southeast Asia and Europe. Jilin Jian Yisheng serves hospitals, pharmacies, and wholesalers as its primary customer base within the pharmaceutical and biotechnology industry segments. Key subsidiaries include Jilin Jian Yisheng Medicine Co., Ltd. for R&D and production facilities in Jilin and Shanghai. In recent developments, the company completed a strategic acquisition of additional stakes in a subsidiary focused on innovative drug pipelines in 2024, enhancing its oncology portfolio. It launched a new biosimilar product line for monoclonal antibodies in late 2024 and formed a partnership with a leading domestic biotech firm for co-development of next-generation targeted therapies. Furthermore, Jilin Jian Yisheng secured a RMB 500 million funding round in early 2025 to support manufacturing expansion and clinical trials for Phase III candidates in cardiovascular indications.